AbbVie (ABBV) EPS (Weighted Average and Diluted) Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
76.98% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
318.57% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-14.16% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-21.46% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
6.98% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
44.22% |
| Dec 31, 2025 |
-9.59% |
| Sep 30, 2025 |
-64.37% |
| Jun 30, 2025 |
0.65% |
| Mar 31, 2025 |
-34.05% |
| Dec 31, 2024 |
-26.18% |
| Sep 30, 2024 |
-20.93% |
| Jun 30, 2024 |
22.39% |
| Mar 31, 2024 |
-27.13% |
| Dec 31, 2023 |
258.30% |
| Sep 30, 2023 |
-8.14% |
| Jun 30, 2023 |
64.83% |
| Mar 31, 2023 |
-59.93% |
| Dec 31, 2022 |
-9.79% |
| Sep 30, 2022 |
20.60% |
| Jun 30, 2022 |
1.34% |
| Mar 31, 2022 |
15.01% |
| Dec 31, 2021 |
56.56% |
| Sep 30, 2021 |
-0.56% |
| Jun 30, 2021 |
-30.66% |
| Mar 31, 2021 |
4.58% |
| Dec 31, 2020 |
-30.66% |
| Sep 30, 2020 |
8.50% |
| Jun 30, 2020 |
-33.64% |
| Mar 31, 2020 |
23.98% |
| Dec 31, 2019 |
30.29% |
| Sep 30, 2019 |
9.11% |
| Jun 30, 2019 |
-20.63% |
| Mar 31, 2019 |
25.74% |
| Dec 31, 2018 |
-49.43% |
| Sep 30, 2018 |
34.74% |
| Jun 30, 2018 |
14.93% |
| Mar 31, 2018 |
40.30% |
| Dec 31, 2017 |
27.22% |
| Sep 30, 2017 |
48.25% |
| Jun 30, 2017 |
20.51% |
| Mar 31, 2017 |
20.22% |
| Dec 31, 2016 |
6.69% |
| Sep 30, 2016 |
17.37% |
| Jun 30, 2016 |
14.08% |
| Mar 31, 2016 |
11.42% |
| Dec 31, 2015 |
-2.08% |
| Sep 30, 2015 |
-9.85% |
| Jun 30, 2015 |
1.23% |
| Mar 31, 2015 |
4.00% |